Evidence that LRAs reactivate HIV-1 replication from primary resting memory CD4 T cells isolated from aviremic long-term-treated HIV-1-infected subjects is limited and remains challenging, while recent clinical trials based on vorinostat, romidepsin, and panobinostat performed in HIV-1 patients under ART showed modest but encouraging effects (20, 26; O. S. Sogaard, presented at AIDS 2014: 20th International AIDS Conference, Melbourne, Australia [www.aids2014.org]). The gene discussed is CD4; the disease is AIDS.